Comparative efficacy and safety of multitarget angiogenesis inhibitor combined with immune checkpoint inhibitor and nivolumab monotherapy as second-line or beyond for advanced lung adenocarcinoma in driver-negative patients: a retrospective comparative cohort study

L Yu; JL Xu; R Qiao; H Zhong; WM Brueckl; RB Zhong

doi:10.21037/tlcr-23-260

Comparative efficacy and safety of multitarget angiogenesis inhibitor combined with immune checkpoint inhibitor and nivolumab monotherapy as second-line or beyond for advanced lung adenocarcinoma in driver-negative patients: a retrospective comparative cohort study

L Yu, JL Xu, R Qiao, H Zhong, WM Brueckl (Co-Autor/-in), RB Zhong

Universitätsklinik für Innere Medizin 3 - Pneumologie, Allergologie, Schlafmedizin

Publikation: Beitrag in Fachzeitschrift › Originalarbeit (Zeitschrift) › Begutachtung

3 Quellenangaben (Web of Science)

Originalsprache	Englisch
Fachzeitschrift	TRANSLATIONAL LUNG CANCER RESEARCH
DOIs	https://doi.org/10.21037/tlcr-23-260
Publikationsstatus	Veröffentlicht - 2023

Zugriff auf Dokument

10.21037/tlcr-23-260

Dieses zitieren

Yu, L., Xu, JL., Qiao, R., Zhong, H., Brueckl, WM., & Zhong, RB. (2023). Comparative efficacy and safety of multitarget angiogenesis inhibitor combined with immune checkpoint inhibitor and nivolumab monotherapy as second-line or beyond for advanced lung adenocarcinoma in driver-negative patients: a retrospective comparative cohort study. TRANSLATIONAL LUNG CANCER RESEARCH. https://doi.org/10.21037/tlcr-23-260

@article{0811c2c8a7634be9a4e9fd7f4fdfdf75,

title = "Comparative efficacy and safety of multitarget angiogenesis inhibitor combined with immune checkpoint inhibitor and nivolumab monotherapy as second-line or beyond for advanced lung adenocarcinoma in driver-negative patients: a retrospective comparative cohort study",

keywords = "1ST-LINE TREATMENT, OPEN-LABEL, CANCER, IMMUNOTHERAPY, DOCETAXEL, PHASE-3, ATEZOLIZUMAB, ANLOTINIB, NSCLC, PD-1",

author = "L Yu and JL Xu and R Qiao and H Zhong and WM Brueckl and RB Zhong",

note = "Brueckl: Department of Respiratory Medicine, Allergology and Sleep Medicine, Paracelsus Medical University, General Hospital Nurnberg, Nuremberg, Germany",

year = "2023",

doi = "10.21037/tlcr-23-260",

language = "English",

journal = "TRANSLATIONAL LUNG CANCER RESEARCH",

issn = "2218-6751",

publisher = "AME PUBLISHING COMPANY",

}

Yu, L, Xu, JL, Qiao, R, Zhong, H, Brueckl, WM & Zhong, RB 2023, 'Comparative efficacy and safety of multitarget angiogenesis inhibitor combined with immune checkpoint inhibitor and nivolumab monotherapy as second-line or beyond for advanced lung adenocarcinoma in driver-negative patients: a retrospective comparative cohort study', TRANSLATIONAL LUNG CANCER RESEARCH. https://doi.org/10.21037/tlcr-23-260

Comparative efficacy and safety of multitarget angiogenesis inhibitor combined with immune checkpoint inhibitor and nivolumab monotherapy as second-line or beyond for advanced lung adenocarcinoma in driver-negative patients: a retrospective comparative cohort study. / Yu, L; Xu, JL; Qiao, R et al.
in: TRANSLATIONAL LUNG CANCER RESEARCH, 2023.

Publikation: Beitrag in Fachzeitschrift › Originalarbeit (Zeitschrift) › Begutachtung

TY - JOUR

T1 - Comparative efficacy and safety of multitarget angiogenesis inhibitor combined with immune checkpoint inhibitor and nivolumab monotherapy as second-line or beyond for advanced lung adenocarcinoma in driver-negative patients: a retrospective comparative cohort study

AU - Yu, L

AU - Xu, JL

AU - Qiao, R

AU - Zhong, H

AU - Brueckl, WM

AU - Zhong, RB

N1 - Brueckl: Department of Respiratory Medicine, Allergology and Sleep Medicine, Paracelsus Medical University, General Hospital Nurnberg, Nuremberg, Germany

PY - 2023

Y1 - 2023

KW - 1ST-LINE TREATMENT

KW - OPEN-LABEL

KW - CANCER

KW - IMMUNOTHERAPY

KW - DOCETAXEL

KW - PHASE-3

KW - ATEZOLIZUMAB

KW - ANLOTINIB

KW - NSCLC

KW - PD-1

U2 - 10.21037/tlcr-23-260

DO - 10.21037/tlcr-23-260

M3 - Original Article (Journal)

C2 - 37323173

SN - 2218-6751

JO - TRANSLATIONAL LUNG CANCER RESEARCH

JF - TRANSLATIONAL LUNG CANCER RESEARCH

ER -

Yu L, Xu JL, Qiao R, Zhong H, Brueckl WM, Zhong RB. Comparative efficacy and safety of multitarget angiogenesis inhibitor combined with immune checkpoint inhibitor and nivolumab monotherapy as second-line or beyond for advanced lung adenocarcinoma in driver-negative patients: a retrospective comparative cohort study. TRANSLATIONAL LUNG CANCER RESEARCH. 2023. doi: 10.21037/tlcr-23-260